Alphatec (NASDAQ:ATEC) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Alphatec (NASDAQ:ATEC) issued its quarterly earnings data on Tuesday. The medical technology company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02, FiscalAI reports. The company had revenue of $212.93 million for the quarter, compared to the consensus estimate of $212.67 million. During the same quarter last year, the business posted ($0.23) earnings per share. Alphatec’s revenue was up 20.4% on a year-over-year basis.

Here are the key takeaways from Alphatec’s conference call:

• Q4 revenue of $213 million (up 20% YoY) with surgical revenue +21%, Q4 Adjusted EBITDA of $33 million and $8 million of free cash flow; full-year revenue was $764 million (up 25%) with Adjusted EBITDA of $93 million (12% margin).
• Management raised full-year 2026 targets to approximately $890 million revenue (17% growth) and $134 million Adjusted EBITDA (15% margin), and expects at least $20 million of free cash flow.
• Executives highlighted a differentiated, integrated procedural ecosystem—EOS / EOS Insight imaging, SafeOp neuromonitoring, upcoming Valence navigation/robotics, 3D‑printed implants and a Theradaptive BMP partnership—which management says is driving surgeon adoption and expanding addressable markets.
• Financial leverage is improving—non‑GAAP gross margin ~70%, SG&A leverage and operating discipline produced meaningful margin expansion and ~41% full‑year drop‑through, enabling the company to self‑fund instrument and inventory investments.
• Management warned that growing deformity volumes and EOS adoption have shifted seasonality (stronger Q2/Q3), which compressed the typical Q4 sequential lift and could complicate short‑term quarter‑to‑quarter comparisons.

Alphatec Price Performance

Shares of ATEC traded up $0.77 during trading hours on Tuesday, reaching $13.93. 6,088,356 shares of the company’s stock traded hands, compared to its average volume of 2,564,407. Alphatec has a 12 month low of $8.81 and a 12 month high of $23.29. The stock has a market cap of $2.07 billion, a PE ratio of -13.39 and a beta of 1.01. The company has a current ratio of 1.99, a quick ratio of 1.24 and a debt-to-equity ratio of 43.02. The firm’s 50 day simple moving average is $17.09 and its 200-day simple moving average is $17.15.

Insider Activity at Alphatec

In related news, Director David R. Pelizzon sold 250,000 shares of the company’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $19.66, for a total value of $4,915,000.00. Following the completion of the transaction, the director directly owned 10,395,045 shares in the company, valued at approximately $204,366,584.70. The trade was a 2.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David Sponsel sold 60,425 shares of the company’s stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $13.79, for a total value of $833,260.75. Following the completion of the transaction, the executive vice president owned 349,500 shares of the company’s stock, valued at $4,819,605. The trade was a 14.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 1,436,125 shares of company stock worth $29,385,878 in the last three months. 22.80% of the stock is owned by insiders.

Institutional Trading of Alphatec

Large investors have recently modified their holdings of the business. Osterweis Capital Management Inc. bought a new stake in Alphatec in the second quarter valued at $37,000. Northwestern Mutual Wealth Management Co. grew its stake in Alphatec by 157.1% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,571 shares of the medical technology company’s stock worth $54,000 after purchasing an additional 1,571 shares during the period. State of Wyoming bought a new position in Alphatec in the second quarter worth $124,000. Focus Partners Wealth purchased a new position in Alphatec during the third quarter valued at $138,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Alphatec by 536.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 14,815 shares of the medical technology company’s stock valued at $164,000 after buying an additional 12,487 shares in the last quarter. 66.35% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Lake Street Capital set a $25.00 price target on Alphatec and gave the stock a “buy” rating in a report on Friday, October 31st. Needham & Company LLC reiterated a “buy” rating and set a $22.00 target price on shares of Alphatec in a research note on Monday, January 12th. Wall Street Zen raised shares of Alphatec from a “hold” rating to a “buy” rating in a report on Saturday, January 31st. Piper Sandler restated an “overweight” rating and set a $25.00 price objective (up from $20.00) on shares of Alphatec in a report on Friday, October 31st. Finally, Stifel Nicolaus began coverage on shares of Alphatec in a report on Tuesday, October 28th. They issued a “buy” rating and a $20.00 price target on the stock. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $22.82.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.